Nureca Limited has informed the Exchange that Record date for the purpose of Record date for AGM -16th May 2025 is 16-May-2025.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 0.6 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nureca Limited's board approved audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025, carrying an unmodified (clean) opinion from statutory auditors B S R & Co. LLP. On a standalone basis, the company reported a net loss, while the consolidated results reflected a net profit. The board gave in-principle approval for merging its wholly owned subsidiary Nureca Technologies Private Limited (FY25 standalone revenue of Rs 228.14 million, net worth Rs 53.94 million) with Nureca Limited (standalone revenue Rs 1,146.40 million, net worth Rs 1,917.38 million), with no new shares to be issued. M/s Singhi & Co. will replace B S R & Co. LLP as statutory auditor for a 5-year term from the 9th AGM, while new internal and secretarial auditors were also appointed. Five directors were re-appointed for a second term, and the 9th AGM was fixed for June 16, 2025 with book closure from June 10 to June 16, 2025.
The wholly owned subsidiary merger will simplify the group structure and cut administrative overheads without diluting shareholders, since no new equity is being issued. The standalone net loss is a point of concern for investors, though consolidated profitability provides some cushion. Routine auditor rotation and director re-appointments suggest governance continuity rather than disruption.